

Alaska Medicaid

Vancocin® (vancomycin)

Available 125mg and 250mg capsules

INDICATIONS:

“VANCOCIN® HCl Capsules may be administered orally for treatment of enterocolitis caused by *Staphylococcus aureus* (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by *C. difficile*. Parenteral administration of vancomycin is not effective for the above indications; therefore, VANCOCIN® HCl Capsules must be given orally for these indications. **Orally administered VANCOCIN® HCl Capsules are not effective for other types of infection.**”¹

Criteria for Approval:

1. Documented trial and failure of metronidazole therapy or has contraindication to metronidazole; AND
2. The patient is being treated for enterocolitis caused by *Staphylococcus aureus* (including methicillin-resistant strains) or antibiotic-associated pseudomembranous colitis caused by *C. difficile*.

Length of Authorization:

Prior authorization may be approved for one course of therapy. Reauthorization may be required for additional treatments.

Dispensing Limit:

The dispensing limit is 80 capsules of either 125mg or 250mg per prescription.

References:

¹ Vancocin® package insert is available at:
< http://www.vancocin.com/~media/Vancocin/Files/Vancocin_PI.ashx > Accessed 12/07/11